Nektar Therapeutics

Traded on the St. Petersburg Stock Exchange
Nektar Therapeutics is a biopharmaceutical company. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances.
Nektar Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Nektar Therapeutics balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Nektar Therapeutics cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Nektar Therapeutics multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Nektar Therapeutics profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Nektar Therapeutics assets
Nektar Therapeutics cash flows

Nektar Therapeutics shares

TickerNameTypeNominal valueISINPrice
NKTR:USNektar TherapeuticsCommon share-US6402681083$0.9135
Nektar Therapeutics news
06.05.2022
Nektar Therapeutics' GAAP loss for 3 months of 2022 was $90.393 million, down 26.5% from $122.967 million in the previous year. Revenue increased by 5% to $24.822 million compared to $23.647 million a year earlier.
Source: {source} pictogram ir.nektar.com
Pictogram next
18.04.2022
Nektar Therapeutics has discontinued trials of its main cancer drug because of numerous failures. Nektar was investigating combinations of bempegaldesleukin with the anti-cancer drugs Opdivo and Keytruda from Bristol Myers and Merck & Co, respectively.
Source: {source} pictogram reuters.com
Pictogram next
01.03.2022
Nektar Therapeutics' GAAP loss for 2021 was $523.837 million, up 17.9% from $444.44 million in the prior year. Revenue decreased 33.4% to $101.907 million from $152.915 million a year earlier.
Source: {source} pictogram ir.nektar.com
Pictogram next
05.11.2021
Nektar Therapeutics' GAAP loss for 9M 2021 was $378.192 million, up 15.6% from $327.237 million in the previous year. Revenue decreased 40.6% to $76.898 million from $129.453 million a year earlier.
Source: {source} pictogram ir.nektar.com
Pictogram next
All Nektar Therapeutics news
General information
Company nameNektar Therapeutics
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
Mailing address455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Websitewww.nektar.com
Information disclosurewww.sec.gov